Values as of: 2024-10-30
COMMON STOCK | Medical Devices |
Last Closing
USD 211.29Change
+1.66 (+0.79)%Market Cap
USD 7.95BVolume
0.73MAnalyst Target
USD 252.80Verdict
Verdict
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Company Website : https://www.penumbrainc.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ABT | Abbott Laboratories |
+1.05 (+0.93%) |
USD 199.13B |
| MDT | Medtronic PLC |
+0.18 (+0.20%) |
USD 118.35B |
| STE | STERIS plc |
+0.52 (+0.23%) |
USD 21.85B |
| ZBH | Zimmer Biomet Holdings Inc |
+5.93 (+5.71%) |
USD 21.23B |
| SNN | Smith & Nephew SNATS Inc |
-0.02 (-0.07%) |
USD 12.71B |
| GMED | Globus Medical |
+0.78 (+1.05%) |
USD 10.01B |
| BIO | Bio-Rad Laboratories Inc |
-1.06 (-0.32%) |
USD 9.26B |
| BIO-B | Bio-Rad Laboratories Inc |
N/A |
USD 9.19B |
| GKOS | Glaukos Corp |
+0.93 (+0.68%) |
USD 7.18B |
| INSP | Inspire Medical Systems Inc |
-2.54 (-1.28%) |
USD 5.82B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| XHE | SPDR® S&P Health Care Eq.. | 2.03 % | 0.35 % |
+0.24 (+0.83%) |
USD 0.21B |
| DOCG:LSE | L&G Healthcare Breakthrou.. | 1.70 % | 0.00 % |
+7.25 (+0.83%) |
USD 0.07B |
| DOCT:LSE | L&G Healthcare Breakthrou.. | 1.70 % | 0.00 % |
+0.10 (+0.83%) |
USD 0.07B |
| PAMC | Pacer Lunt MidCap Multi-F.. | 1.16 % | 0.00 % |
-0.07 (0.83%) |
USD 0.06B |
| BWZ | SPDR® Bloomberg Short Te.. | 0.00 % | 0.35 % |
-0.05 (0.83%) |
N/A |
| EPU | iShares MSCI Peru ETF | 0.00 % | 0.59 % |
-0.41 (0.83%) |
USD 0.09B |
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -16.00% | 55% | F | 19% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -16.00% | 55% | F | 27% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 8.88% | 58% | F | 38% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 8.88% | 58% | F | 45% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 31.92% | 71% | C- | 68% | D+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 31.92% | 71% | C- | 68% | D+ | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 13.21% | 65% | D | 73% | C | ||
| Dividend Return | 13.21% | 65% | D | 69% | C- | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 47.95% | 29% | F | 20% | F | ||
| Risk Adjusted Return | 27.54% | 58% | F | 44% | F | ||
| Market Capitalization | 7.95B | 70% | C- | 83% | B | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
